Form 8-K - Current report:
SEC Accession No. 0001683168-25-003513
Filing Date
2025-05-14
Accepted
2025-05-14 08:27:52
Documents
15
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K xenetic_8k.htm   iXBRL 8-K 29895
2 PRESS RELEASE xenetic_ex9901.htm EX-99.1 16383
6 GRAPHIC image_001.gif GRAPHIC 5333
  Complete submission text file 0001683168-25-003513.txt   232142

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE xbio-20250514.xsd EX-101.SCH 3020
4 XBRL LABEL FILE xbio-20250514_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE xbio-20250514_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_8k_htm.xml XML 3572
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37937 | Film No.: 25942771
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)